Fundz

NurExone Biologic Inc. Announces Acquisition of Master Cell Bank to Enhance Exosome-Based Therapies.

Jan 08, 2025
HaifaBiotechnology

Product Description

NurExone Biologic Inc. has acquired a master cell bank from a U.S. manufacturer to ensure a stable supply chain for exosome-based therapies. This acquisition is a strategic move to advance revenue-generating opportunities for innovative therapeutic applications.

Company Information

Company

NurExone Biologic

Location

MINUS 1 ENTRY, GROUND FLOOR OF BLDG B

Haifa, Haifa District, Israel

About

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Fundz sees it the moment NurExone Biologic ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Lior hidden

hidden
hidden

Limor hidden

hidden
hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for NurExone Biologic's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

NurExone Biologic shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.